|
ProBiotix Health PLC on Friday announced a new partnership with South Korean consumer health and wellness products firm TopHealth. The Wakefield, England-based life sciences business said the deal granted TopHealth the rights to sell its finished consumer products direct to consumers in South Korea. Products included under the terms were the ProBiotix CholBiome brand, YourBiotix private turnkey solutions and TopHealth’s own consumer brand products. The first phase of the partnership will focus on the import and direct sale of CholBiome X3 to consumers. The probiotics dietary supplements market in South Korea is currently worth an estimated £350 million, which is expected to rise to £870 million by 2030. ‘We are pleased to have managed to secure a market leader like Tophealth. It is a company with a proven track record of building strong businesses in the probiotic sector, and today ranks as one of the leading brand innovators in the South Korean supplement market,’ said ProBiotix Health Chief Executive Officer Steen Andersen. ‘South Korea poses a perfect fit for our value proposition being a high price growth market, with an increasing focus by consumers on probiotic supplements to help manage their health. ‘TopHealth has worked diligently with the influencer market, harnessing their large followings to influence consumer purchasing decisions. We expect this increasing awareness to drive demand for our products in the years ahead.’ Shares in ProBiotix Health were last traded at 8.08 pence in London on the Aquis Exchange on Friday afternoon. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
